OctoPlus lands formulation work

Netherlands-based drug-delivery specialist OctoPlus will perform formulation development and clinical manufacturing for an unnamed mid-sized European drug maker. The work encompasses three products, now in Phase I to Phase III clinical development.

The contract "significantly contributes" to its annual revenues, the company says.

In June, OctoPlus opened and began production in a manufacturing facility in Leiden, the culmination of a 2-1/2-year effort. The facility, which is being used to produce final drug product, is approved by Dutch authorities to manufacture drugs to international GMP guidelines. The plant more than doubles OctoPlus manufacturing capacity. It also allows the company to make products covering all phases of preclinical drug development, as well as small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.

- here's the contract announcement
- see the new facility release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.